Phase 3 trials – Talk Bio

Incyte’s oral HS drug hits study goals, but fails to excite investors

1 month ago talkbio0Tagged Effectiveness, Hidradenitis, Inhibitor, investor, Janus kinase 1, Phase 3 trials, povorcitinib, regulatory, suppurativa

povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission

Merck’s HIV Combo Treatment Advances Towards FDA Filing

1 month ago talkbio0Tagged DOR/ISL, doravirine/islatravir, once-daily, oral regimen, Phase 3 trials, Submission, United States Food and Drug Administration, viral suppression

Doravirine/islatravir (DOR/ISL) combination, Phase 3 trials, Viral suppression, Once-daily oral regimen, FDA submission

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

3 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation

Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials

4 months ago talkbio0Tagged CNS disorder, Metabolic Diseases, Phase 3 trials, REL-1017, Relmada, strategic alternatives

Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders

Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017

5 months ago talkbio0Tagged Clinical Trials, Drug Development, MDD, Phase 3 trials, REL-1017, Relmada, Strategic Options, Unipolar Depression

Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development

NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations

5 months ago talkbio0Tagged CETP, cholesterol-lowering drugs, Expectations, inhibitors, investor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 trials

NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction

Pfizer’s Next Challenge: Phase 3 Trials for Breakthrough Cancer Therapies

7 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Oncology Pipeline, Pfizer, Phase 3 trials

Pfizer, Phase 3 trials, cancer therapies, oncology pipeline, clinical trials

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

8 months ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation